Inhibition of CD1d-mediated antigen presentation by the transforming growth factor-β/Smad signalling pathway

Immunology

Volumn 143, Issue 4, 2014, Pages 679-691

  Bailey, Jennifer C ^a   Iyer, Abhirami K ^a   Renukaradhya, Gourapura J ^a   Lin, Yinling ^a   Nguyen, Hoa ^a   Brutkiewicz, Randy R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen presentation processing; Rodent; Signal transduction

Indexed keywords

CD1D ANTIGEN; HLA ANTIGEN CLASS 2; LIPID; MITOGEN ACTIVATED PROTEIN KINASE P38; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; ANTIGEN PRESENTATION; BIOLOGICAL MODEL; CELL LINE; DRUG EFFECTS; FEMALE; IMMUNOLOGY; LYSOSOME; METABOLISM; MOUSE; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD1D; CELL LINE; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; LIPIDS; LYSOSOMES; MICE; MODELS, IMMUNOLOGICAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84911977902     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12353     Document Type: Article

References (50)

1. Dougan SK, Kaser A, Blumberg RS. CD1 expression on antigen-presenting cells. Curr Top Microbiol Immunol 2007; 314:113-41.
2. Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol 2007; 7:929-41.
3. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 2013; 13:101-17.
4. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011; 11:131-42.
5. Travis MA, Sheppard D. TGF-β activation and function in immunity. Annu Rev Immunol 2014; 32:51-82.
6. Prud'homme GJ. Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007; 87:1077-91.
7. Schmierer B, Hill CS. TGFβ-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007; 8:970-82.
8. Souchelnytskyi S, ten Dijke P, Miyazono K, Heldin CH. Phosphorylation of Ser165 in TGF-β type I receptor modulates TGF-β1-induced cellular responses. EMBO J 1996; 15:6231-40.
9. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massague J. TGF β signals through a heteromeric protein kinase receptor complex. Cell 1992; 71:1003-14.
10. Brutkiewicz RR, Willard CA, Gillett-Heacock KK et al. Protein kinaseCδ is a critical regulator of CD1d-mediated antigen presentation. Eur J Immunol 2007; 37:2390-5.
11. Gallo RM, Khan MA, Shi J, Kapur R, Wei L, Bailey JC, Liu J, Brutkiewicz RR. Regulation of the actin cytoskeleton by Rho kinase controls antigen presentation by CD1d. J Immunol 2012; 189:1689-98.
12. Khan MA, Gallo RM, Brutkiewicz RR. Anthrax lethal toxin impairs CD1d-mediated antigen presentation by targeting the extracellular signal-related kinase 1/2 mitogen-activated protein kinase pathway. Infect Immun 2010; 78:1859-63.
13. Khan MA, Gallo RM, Renukaradhya GJ, Du W, Gervay-Hague J, Brutkiewicz RR. Statins impair CD1d-mediated antigen presentation through the inhibition of prenylation. J Immunol 2009; 182:4744-50.
14. Khan MA, Sriram V, Renukaradhya GJ, Du W, Gervay-Hague J, Brutkiewicz RR. Apoptosis-induced inhibition of CD1d-mediated antigen presentation: different roles for caspases and signal transduction pathways. Immunology 2008; 125:80-90.
15. Renukaradhya GJ, Khan MA, Shaji D, Brutkiewicz RR. Vesicular stomatitis virus matrix protein impairs CD1d-mediated antigen presentation through activation of the p38 MAPK pathway. J Virol 2008; 82:12535-42.
16. Renukaradhya GJ, Webb TJ, Khan MA, Lin YL, Du W, Gervay-Hague J, Brutkiewicz RR. Virus-induced inhibition of CD1d1-mediated antigen presentation: reciprocal regulation by p38 and ERK. J Immunol 2005; 175:4301-8.
17. Yu L, Hebert MC, Zhang YE. TGF-β receptor-activated p38 MAP kinase mediates Smad-independent TGF-β responses. EMBO J 2002; 21:3749-59.
18. Carlson CM, Turpin EA, Moser LA et al. Transforming growth factor-beta: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis. PLoS Pathog 2010; 6:e1001136.
19. Pickup M, Novitskiy S, Moses HL. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 2013; 13:788-99.
20. Roberts TJ, Sriram V, Spence PM et al. Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. J Immunol 2002; 168:5409-14.
21. + T cell lymphoma by natural killer T (NKT) cells. Proc Natl Acad Sci USA 2002; 99:8197-202.
22. - T cells in mice and humans. J Exp Med 1994; 180:1097-106.
23. + NK T lymphocytes. J Immunol 1998; 161:3271-81.
24. Gui M, Li J, Wen LJ, Hardy RR, Hayakawa K. TCR β chain influences but does not solely control autoreactivity of Vα14J281T cells. J Immunol 2001; 167:6239-46.
25. Pathak SS, Blum JS. Endocytic recycling is required for the presentation of an exogenous peptide via MHC class II molecules. Traffic 2000; 1:561-9.
26. Ronger-Savle S, Valladeau J, Claudy A, Schmitt D, Peguet-Navarro J, Dezutter-Dambuyant C, Thomas L, Jullien D. TGFβ inhibits CD1d expression on dendritic cells. J Invest Dermatol 2005; 124:116-8.
27. Tatsumi T, Takehara T, Yamaguchi S et al. Decreased expressions of CD1d molecule on liver dendritic cells in subcutaneous tumor bearing mice. J Hepatol 2008; 49:779-86.
28. Yue J, Mulder KM. Activation of the mitogen-activated protein kinase pathway by transforming growth factor-β. Methods Mol Biol 2000; 142:125-31.
29. Salio M, Silk JD, Cerundolo V. Recent advances in processing and presentation of CD1 bound lipid antigens. Curr Opin Immunol 2010; 22:81-8.
30. Jayawardena-Wolf J, Benlagha K, Chiu YH, Mehr R, Bendelac A. CD1d endosomal trafficking is independently regulated by an intrinsic CD1d-encoded tyrosine motif and by the invariant chain. Immunity 2001; 15:897-908.
31. Kang JS, Liu C, Derynck R. New regulatory mechanisms of TGF-β receptor function. Trends Cell Biol 2009; 19:385-94.
32. Massague J. TGFb signalling in context. Nat Rev Mol Cell Biol 2012; 13:616-30.
33. De Libero G, Mori L. Novel insights into lipid antigen presentation. Trends Immunol 2012; 33:103-11.
34. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995; 7:529-34.
35. Prigozy TI, Naidenko O, Qasba P et al. Glycolipid antigen processing for presentation by CD1d molecules. Science 2001; 291:664-7.
36. Gelin C, Sloma I, Charron D, Mooney N. Regulation of MHC II and CD1 antigen presentation: from ubiquity to security. J Leukoc Biol 2009; 85:215-24.
37. Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987; 84:5788-92.
38. Wahl SM, Allen JB, Weeks BS, Wong HL, Klotman PE. Transforming growth factor β enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci USA 1993; 90:4577-81.
39. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med 2000; 342:1350-8.
40. Wrzesinski SH, Wan YY, Flavell RA. Transforming growth factor-β and the immune response: implications for anticancer therapy. Clin Cancer Res 2007; 13:5262-70.
41. Lebman DA, Edmiston JS. The role of TGF-β in growth, differentiation, and maturation of B lymphocytes. Microbes Infect 1999; 1:1297-304.
42. Andrieux G, Le Borgne M, Theret N. An integrative modeling framework reveals plasticity of TGF-β signaling. BMC Syst Biol 2014; 8:30.
43. Lee YJ, Han Y, Lu HT et al. TGF-β suppresses IFN-γ induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J Immunol 1997; 158:2065-75.
44. Dong Y, Tang L, Letterio JJ, Benveniste EN. The Smad3 protein is involved in TGF-β inhibition of class II transactivator and class II MHC expression. J Immunol 2001; 167:311-9.
45. Cross D, Cambier JC. Transforming growth factor β 1 has differential effects on B cell proliferation and activation antigen expression. J Immunol 1990; 144:432-9.
46. Berger AC, Roche PA. MHC class II transport at a glance. J Cell Sci 2009; 122:1-4.
47. Li MO, Sanjabi S, Flavell RA. Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006; 25:455-71.
48. Marie JC, Liggitt D, Rudensky AY. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-β receptor. Immunity 2006; 25:441-54.
49. Doisne JM, Bartholin L, Yan KP et al. iNKT cell development is orchestrated by different branches of TGF-β signaling. J Exp Med 2009; 206:1365-78.
50. Kumar V, Delovitch TL. Different subsets of natural killer T cells may vary in their roles in health and disease. Immunology 2014; 142:321-36.